Q4 Results Live Updates
AstraZeneca FY26 revenue rises 33%, recommends ₹36 dividend
27 May 26AstraZeneca Pharma India Limited reported a 33% YoY increase in total revenue to ₹22,755.80 Mn for FY26, driven by growth in Oncology and Biopharmaceuticals. The Board recommended a ₹36 per share dividend and approved the re-appointment of an Independent Director and Statutory Auditors. The company secured 11 regulatory approvals during the year, including new indications for Durvalumab and Osimertinib.
view all stories

Latest Market Updates
Today's Top Gainers





Today's Top Losers





Today's Top Gainers





Today's Top Losers













































